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Mycoplasma bacteria were discovered and have been explored in published literature for 
well over a century. Most notably, these organisms lack a cell wall and cause disease in animals 
and humans depending on the bacterial species. This report explores the characteristics of 
Mycoplasma bovis, mycoides, and ovipneumoniae and their associated challenges in controlling 
disease in ruminants, current strategies for mitigation, and possible utilization of vaccines for 
prevention. Mycoplasma bovis, one of the more pathogenic strains, affects cattle and manifests 
itself in causing mastitis, pneumonia, ocular signs, arthritis, and other symptoms. Economic 
losses from Mycoplasma bovis are incurred from the high morbidity rates. Laboratory 
diagnostics are necessary to confirm this causative agent. Treatment of Mycoplasma bovis, 
including the use of effective antimicrobials, is still debated. Sound herd management, as well as 
potential vaccination, are critical in the prevention of mycoplasmas within the United States. 
Mycoplasma mycoides, also affecting cattle, is the bacterium causing contagious bovine pleuro-
pneumonia. Today, this condition primarily affects herds in Asia and Africa; however, American 
and British economies were affected by a suspected and primary diagnosis of this disease in the 
mid- to late- 1800s. Transmitted via aerosols, Mycoplasma mycoides causes primarily respiratory 
signs in adult cattle and arthritis in calves. Only a few different diagnostic tests can confirm 
Mycoplasma mycoides, but a confirmation, aside from clinical signs, is made post-mortem. There 
have been reports of antimicrobials demonstrating effectiveness with regard to combating 
Mycoplasma mycoides; however, there is no standard protocol for treatment at this time. Sanitary 
and medical prophylaxis is recommended to control and prevent Mycoplasma mycoides from 
infiltrating a herd. Finally, Mycoplasma ovipneumoniae has been implicated in domestic flocks 
of sheep and goats in addition to wildlife. Respiratory morbidities and high transmissibility of 
  
Mycoplasma ovipneumoniae result in significant losses. A polymerase chain reaction (PCR) or 
competitive enzyme-linked immunosorbent assay (ELISA) can be used to diagnose the bacteria. 
Separating domestic flocks from wildlife is imperative in protecting both groups. Strategies to 
combat mycoplasmas include individual animal testing, herd surveys, and isolation of animals 
before exposure to the herd, among others. Vaccination strategies should be more aggressively 
investigated. In conclusion, there is much to be done in understanding and controlling this 
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Chapter 1 - Introduction 
With more than 120 species, mycoplasmas are the causative agent of a multitude of 
conditions in both humans and animals. This report aims to discuss three of the more pathogenic 
species of mycoplasma in ruminants: Mycoplasma bovis, mycoides, and ovipneumoniae. These 
three species were specifically selected due to the relevance in cattle and wildlife in Alaska, 
which aligns closely with the author’s interests. 
 
 Background of Mycoplasma 
 Etymology 
The term “mycoplasma” was first coined in a paper by German botanist, plant 
pathologist, and mycologist, Albert Bernhard Frank, in 1889. The term was also subsequently 
used by Swedish plant pathologist, mycologist, and taxonomist, Jakob Eriksson, in 1897. These 
scientists used the term to signify a close association between plant-invading fungi or other 
microorganisms and their host cells (Krass and Gardner, 1973). In 1929, Polish microbiologist 
and politician Julien Nowak used mycoplasma in a taxonomic context to describe the organism 
involved in bovine pleuro-pneumonia. Later, E. A. Freundt and D. G. Edward more recently used 
mycoplasma to classify organisms as the causative agents of pleuro-pneumonia in cattle (Krass 
and Gardner, 1973).  
 
 Classification 




Mycoplasmas are prokaryotes and the smallest free-living, self-replicating 
microorganisms (Maglaras and Koenig, 2015). The defining characteristic of this class is that all 
members lack a protective cell wall. Due to this, they are easily damaged when they are outside 
of a host and can be difficult to stain in the laboratory using routine bacterial staining methods. 
Though mycoplasma species stain using Gram stain, and based on the phenotype, are considered 
Gram-negative, this is not due to the lack of peptidoglycans in their cell wall; as stated, this 
genus lacks a cell wall altogether. It is perhaps more correct to classify them as a Gram-positive 
bacterium that has lost the cell wall, and therefore, have lost the capacity to retain any crystal 
violet dye. The Giemsa stain is an alternative staining option. Mycoplasmas contain a small 
genome (ranging from 540-1300 kb) (Hardison 1997), and thus, have limited metabolic 
capability; this is due to a limited amount of proteins (enzymes) able to support growth. These 
microorganisms draw nutrients from mucosal surfaces after colonization. There are hemotropic 




Chapter 2 - Mycoplasma bovis 
 Introduction to Disease 
Mycoplasma bovis is a significant pathogen of cattle causing disease with impacts 
affecting the welfare of the animals as well as the economics of the farming community. In fact, 
M. bovis is regarded as one of the more pathogenic species of the genus. M. bovis was first 
detected in 1961 in the United States as a cause of bovine mastitis. Since the 1960s, M. bovis has 
been found in most countries around the world (Nicholas et al., 2003). True to the mollicute 
class, M. bovis is small and pleomorphic, meaning that this bacterial species can somewhat alter 
its characteristics to adapt to its environment. The genome size is 1,080 kbp (Nicholas et al., 
2003), and it has a low GC ratio of about 29.3%, making it relatively unstable (Calcutt et al., 
2018). Most mycoplasmas are fragile in the environment; however, M. bovis can survive at 4C 
for about two weeks in sponges and milk and for longer than two weeks in water. Survival rates 
decrease significantly at higher temperatures (Nicholas et al., 2003). M. bovis is not a food safety 
risk for humans. 
 
 Economics 
One published estimate of the economic impact of M. bovis in 1999 stated that the United 
States experiences approximately $108 million in losses as a result of the bacteria (Rosengarten 
and Citti, 1999). These losses are attributed more toward bovine mastitis than respiratory disease 
in dairy cattle, with infection rates of up to 70% in a herd (Rosengarten and Citti, 1999). A bulk 
milk tank culture over nine years in New York revealed that about 2.3% of tank samples were 
found positive for M. bovis. Samples retrieved from surveys in Iowa had similar results. Iowa 
herds with tank-positive cultures had culling rates of 30-70% of cows. Enzootic pneumonia 
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caused by M. bovis also affect veal calves and feedlot cattle. These losses are seen as loss of 
weight gain and loss in carcass values. Such losses, as of 1999, stood at approximately $32 
million per year (Rosengarten and Citti, 1999). In all classes of cattle, M. bovis has been isolated 
from the genital tract as well as in aborted fetuses. Contaminated bovine semen is seen as a 
medium for transmission, which impacts the artificial insemination industry (Rosengarten and 
Citti, 1999). Other costs include general reduced production, drugs and treatment labor, death 
and culling losses, diagnostics, prevention strategies, control implementation, and costs related to 
decreases in animal welfare. Disease associated with M. bovis is typically chronic, and thus, 
costs per case are higher when compared to other pathogens in the bovine respiratory disease 
complex (Maunsell et al., 2011).   
 
 Transmission & Clinical Signs and Symptoms 
M. bovis is highly contagious, and transmission was first thought to occur solely via 
aerosol. However, calves are at a high risk of infection when fed milk from infected cows. Some 
experimental studies have shown that the teat canal and genital tract can be means of infection 
passed from dam to fetus. Contaminated semen used for artificial insemination has been traced to 
female infections as well. Additionally, M. bovis has the capability to survive in bedding. Cattle 
are also most susceptible to infection given climatic changes, overcrowding conditions, or 
translocation (Calcutt et al., 2018). More details are described below with regard to common 
clinical disease manifestations associated with M. bovis infections.  
 
Mastitis: The degree of mastitis in a herd can vary from endemic subclinical disease to severe 
outbreaks. In some subclinical infections, cows do not experience an increase in somatic cell 
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counts or a reduction in milk production, making it difficult to detect clinically. M. bovis does 
not discriminate, in that cows of any age or stage of lactation are susceptible. Clinical disease 
presents nonspecific signs. More than one quarter is typically affected, and there may be a 
dramatic decrease in milk production and/or mild signs of systemic ailments. The mammary 
gland itself could be swollen but not necessarily painful, and secretions can vary from minimally 
abnormal to gritty or purulent with a possible brownish hue. Clinical disease can last for several 
weeks, and antimicrobial resistance is common. Potential accompanying conditions include 
arthritis, synovitis, joint effusion, or respiratory disease. A return to homeostasis in the animal is 
possible, but it can be a slow process (Maunsell et al., 2011). 
 
Pneumonia: Pneumonia caused by M. bovis can occur in any age of cattle. Clinical signs are 
nonspecific and may include fever, tachypnea, dyspnea, decreased appetite, and coughing with or 
without nasal discharge. Chronically affected animals will experience inadequate weight gain. 
Potential accompanying conditions include otitis media and arthritis. Chronic pneumonia and 
polyarthritis syndrome (CPPS) can occur in beef cattle several weeks after arrival to a feedlot 
(Maunsell et al., 2011). 
 
Otitis media: Otitis media caused by M. bovis occurs in dairy or beef calves as either enzootic 
disease or as an outbreak. Clinical signs can be unilateral or bilateral. Calves experiencing early 
or mild cases of otitis media will maintain alertness and a sufficient appetite; however, disease 
progression will progress to fever and anorexia. Ear droop and ptosis are a result of ear pain and 
cranial nerve VII deficits. Calves with ear pain will also shake their head and scratch and/or rub 
their ears. Eyelid paresis can cause the secondary effects of epiphora and exposure keratitis. If 
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the tympanic membrane of the ear has been ruptured, purulent aural discharge can be evident. 
Accompanying conditions of pneumonia and/or arthritis are common. As sequelae to otitis 
media, otitis interna and vestibulocochlear nerve deficits can occur. A common clinical sign of 
otitis interna is head tilt, but certain animals will display nystagmus, circling, falling, or drifting 
toward the side of the lesion and vestibular ataxia. Meningitis can develop in advanced cases of 
otitis media and otitis interna. Additionally, spontaneous regurgitation, loss of pharyngeal tone, 
and dysphagia can occur. This is suggestive of glossopharyngeal nerve dysfunction with or 
without vagal nerve dysfunction (Maunsell et al., 2011). 
 
Arthritis, synovitis, and periarticular infections: Arthritis caused by M. bovis can affect cattle of 
any age. Cases are typically sporadic and will accompany pneumonia or mastitis, and although 
most of these cases are reported in calves and dairy cows, CPPS is more likely to be reported in 
feedlot cattle. Clinical signs are typical of septic arthritis, including acute non-weight bearing 
lameness with joint swelling, pain, and heat upon palpation. Signs may also include a febrile and 
anorectic animal. Tendon sheaths and particular soft tissue involvement is common. Large 
rotator joints (hip, stifle, hock, shoulder, elbow, and carpal) are commonly affected. Other joints, 
such as the fetlock or even the atlantooccipital joint, can be involved. It is common for the 
animal to respond poorly to treatment (Maunsell et al., 2011). 
 
Keratoconjunctivitis: M. bovis can be isolated from the conjunctiva of both healthy and diseased 
animals. The involvement in infectious keratoconjunctivitis is not well understood or reported, 
and it is mainly considered a predisposing or coinfecting agent. However, it was the only 
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pathogen isolated in an outbreak of infectious keratoconjunctivitis in calves where this ailment 
was followed by cases of pneumonia and arthritis (Maunsell et al., 2011). 
 
Decubital abscesses: One report stated that 50 calves developed M. bovis-infected decubital 
abscesses over the brisket and joints. Some of these affected calves had M. bovis-associated 
pneumonia as well (Maunsell et al., 2011).  
 
Cardiac disease: M. bovis was identified with the bacteria Histophilus somni in the hearts of 4 of 
92 feeder calves dying from myocarditis. Additionally, a heifer with clinical signs of cardiac 
insufficiency was found to have mural and valvular endocarditis with M. bovis isolated from this 
case of chronic active fibrinopurulent endocarditis (Maunsell et al., 2011). 
 
Genital disorders: There is scant evidence to support an important role for M. bovis in naturally 
occurring bovine reproductive disease. However, in isolated and mainly experimental cases, M. 
bovis has been linked to genital infections and abortions in cows and seminal vesiculitis in bulls 
(Maunsell et al., 2011). 
 
 Diagnosis 
Laboratory diagnosis is necessary for pathogen identification as clinical and pathological 
signs are not unique to M. bovis. Thomas et al. (2002) noted that sampling by bronchoalveolar 
lavage was more indicative of lower respiratory airway pathogens, including M. bovis, than nasal 
swabs. M. bovis grows well in a variety of media and produces colonies within 3-5 days of 
incubation. In the correct medium, M. bovis produces films and spots, and gives the broth an 
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orange hue. Growth inhibition, film inhibition, fluorescent antibody, or metabolic inhibition tests 
can be used to identify mycoplasma using hyperimmune rabbit serum (Nicholas et al., 2003). A 
commercial sandwich enzyme-linked immunosorbent assay (ELISA) exists for M. bovis in which 
specific monoclonal antibodies fixed to a microplate capture the M. bovis antigen from the 
medium. M. bovis can be over grown by opportunistic mycoplasmas and sometimes antigenic 
variability of strains can make serological tests untrustworthy. In these conditions, polymerase 
chain reaction (PCR) can be more readily utilized. PCRs have been used to detect M. bovis from 
milk (even preservative-treated milk) and nasal swabs (Nicholas et al., 2003). Combined testing 
for both prior exposure (by detecting anti-M. bovis antibodies) and current infection (by 
detecting M. bovis antigen or nucleic acid) would provide the best control measures against new 
and potentially latent infections. However, if both tests yield a negative result, the “gold 
standard” would be to culture the organism (Calcutt et al., 2018).   
 
 Treatment 
It was once considered that diseases and conditions resulting from M. bovis were resistant 
to any chemotherapy. However, antibiotics are typically prescribed to reduce secondary bacterial 
infections and do not effectively treat the mycoplasma. Evidence from Ayling et al. (2000) 
implies that European M. bovis strains are developing resistance to antibiotics traditionally used 
for mycoplasma treatment; more specifically, these antibiotics include oxytetracyclines, 
tilmicosin, and spectinomycin. On a scale of relative effectiveness, the fluoroquinolones are 
deemed effective, but their use in animals remains contentious (Nicholas et al., 2003).  
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 Prevention & Control 
The inability of chemotherapies to control these infections has caused a shift in focus to 
vaccination (Perez-Casal et al., 2017). Currently, there are no vaccines available in Europe. In 
the United States, there are a few commercially available vaccines (including autogenous and 
bacterin vaccines), although there is minimal data supporting their effectiveness (Calcutt et al., 
2018). These United States vaccines are not licensed for use outside of the country (Calcutt et al., 
2018). 
Enforcing a closed herd policy can be critical in managing mycoplasma infections and 
disease. Additionally, confirming that animals are free of infection by testing for anti-M. bovis 
antibodies and appropriate quarantine measures with consistent health assessments are effective 
strategies for keeping a herd free of M. bovis. Good management practices and proper ventilation 
will also assist in control measures. Examples of good management practices include 
introduction of animals tested free of M. bovis, routine cleaning and disinfection of premises, 
prohibited feeding of infected milk, regular observation of animals, isolation of infected animals, 






Chapter 3 - Mycoplasma mycoides 
 Introduction to Disease 
As noted, mycoplasmas are significant bacterial livestock pathogens worldwide. 
Mycoplasma mycoides subsp. mycoides and Mycoplasma capricolum subsp. capripneumoniae 
are two members of the “Mycoplasma mycoides cluster” (Fischer et al., 2012). These bacteria are 
the causative agents of contagious bovine pleuro-pneumonia (CBPP) and contagious caprine 
pleuro-pneumonia. Both of these conditions cause profound losses in livestock, particularly in 
Africa and Asia as of today, and threaten re-introduction to disease-free countries such as Europe 
and the United States (Fischer et al., 2012). For the scope of this report, the focus will remain on 
M. mycoides affecting cattle and certain related bovids. Humans are not susceptible to CBPP, so 
there is no zoonotic risk (OIE 2019).  
M. mycoides was characterized for the first time in 1898. CBPP was first noted in Europe 
and was introduced into Africa, North America, Australia, and New Zealand during colonial 
expeditions of livestock trade movements in the 18th and 19th centuries (Fischer et al., 2012).  
M. mycoides does not survive for long in the environment under warm conditions; it can 
survive outside of its host for up to three days in tropical areas, and up to two weeks in temperate 
climates. If frozen, the bacteria can survive for more than ten years. With regard to temperature, 
it can be inactivated within one hour at 56C and two minutes at 60C. The bacteria can also be 




Although economic impacts of M. mycoides occur in Africa and Asia at the present time, 
an example of how detrimental this threat of disease can be is seen when analyzing transatlantic 
trading between North America and Great Britain in the mid- to late-1800s.  
As early as 1843, pleuro-pneumonia had been an issue between the United States and 
England as a result of U.S. Congress remaining lenient about tariffs on imports of breeding 
stock. A House report (“House Agriculture Committee Report on Cattle Disease”) from the 36th 
Congress notes an infiltration of ruminant pleuro-pneumonia from England to Brooklyn, New 
York aboard the steamship Washington. Furthermore, when pleuro-pneumonia had found its way 
into New Jersey from Britain in 1847, it was contained as the concerning farmer slaughtered his 
infected herd. Pleuro-pneumonia was introduced once again to the U.S. in 1859, although this 
shipment of infected cattle originated from Holland enroute to Massachusetts. However, in the 
summer and fall of 1878, outbreaks of pleuro-pneumonia were evident in the District of 
Columbia, Maryland, Virginia, New Jersey, and New York (Kastner 2003).  
The bulk of the story, as told by Kastner et al. (2005), begins in January 1879. At this 
time, the steamship Ontario, carrying a shipment of over 200 cattle from North America, was 
headed from Maine, U.S., to Liverpool, England. Meanwhile, veterinary authorities in both 
London and Liverpool, England, were planning the enforcement of a new Foreign Animals 
Order. This order, adopted under the Contagious Diseases (Animals) Act of 1878, stated that all 
livestock imports were to be slaughtered within ten days of arrival to port. This act included 
exempted countries, of which the U.S. and Canada were included. With these exemptions, 
animals from particular countries could be transported inland for further pre-harvest practices 
under the condition that they were deemed disease-free at port. There had been some reports by 
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certain veterinary professionals that the eastern U.S. harbored CBPP. This led to the question of 
how long the U.S. would remain exempt from the slaughter order at U.K. ports. These reports 
proved detrimental for those involved in the economics of North American cattle trading. Some 
businessmen from both the U.S. and the U.K. speculated that if livestock imports ceased, the 
supply of meat would decrease while prices would increase. When the Ontario arrived in 
England, there was just under 200 animals, as two of them had died. The Veterinary Inspector 
for the local authority of Liverpool did a post-mortem analysis of these two animals and 
suspected CBPP. The Inspector relayed these lung samples to the Veterinary Department of the 
Privy Council of London, who confirmed CBPP. There was a subsequent slaughter order for the 
entire shipment aboard the Ontario. Upon slaughter, the Privy Council veterinary authorities 
noted that many of the cargo had respiratory inflammation indicative of cold weather. 
Additionally, though, they noted the characteristic lesions of CBPP in twelve of the animals’ 
lungs. The American exemption from the immediate slaughter order was retracted the next day. 
This proclamation wreaked havoc. The U.S. Treasury Secretary haphazardly created a program 
to inspect and certify live cattle; the U.S. Commissioner of Agriculture meanwhile had sent two 
men to inspect Chicago and New York stockyards. Few individuals, including a professor from a 
veterinary college in Edinburgh and a shipping mogul, questioned the final diagnosis of CBPP 
within the U.K. Thus, the “disease-free west” argument was born: that CBPP was in circulation 
in the eastern U.S. but was non-existent in the western states where the cattle originated (prior to 
being transported to Maine for shipment to England). Importers from Liverpool called in 
veterinary experts from around the U.K. to corroborate the Privy Council’s diagnosis. Of the 
three consultants, two were definite in their diagnosis of CBPP, while one attributed the lesions 
to conventional bronchitis. This brought on debate within the transatlantic veterinary community, 
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which continued for some time. It is important to recognize that at this period of time, 
microbiological analysis was practically in its infancy. Thus, inspectors utilized gross visual 
analysis for diagnosis. The fact that CBPP was contagious was clear, but the specific causes of 
the disease (M. mycoides) would remain elusive until 1898. Without a solid program for 
inspecting and certifying cattle in the U.S., the U.K. had reason to deny claims and questions 
regarding CBPP. The issue resolved itself after 1900, when the demand for beef in an 
exponentially growing U.S. population took attention away from U.K. markets (Kastner et al., 
2005). The most recent report of CBPP in Europe was in Portugal in 1999. Since then, Europe 
has been considered CBPP-free (CABI 2019). According to the USDA APHIS (U.S. Declaration 
of Disease Freedom), the United States has been declared CBPP-free since 1892 (USDA 2019).  
 
 Transmission & Clinical Signs and Symptoms 
Incubation of CBPP is typically 1-4 months, but longer time periods have been observed. 
Transmission of M. mycoides/CBPP occurs through close, direct contact and inhalation of 
droplets from infected, coughing bovines; however, under particular atmospheric conditions 
including humidity and wind, the bacteria can be transmitted via aerosols over a longer distance 
(~200 meters). The bacteria can also be found in saliva, urine, fetal membranes, and uterine 
discharges. Transmission via the placenta is possible. Transporting cattle is usually a stressor in 
the spread of CBPP (OIE 2009). 
Initial clinical signs in the adult may present as a depressed animal with inappetence and 
a moderate fever, to be followed by coughing, pain in the thoracic cavity, and an increased 
respiratory rate. As pneumonia progresses, the animal will develop labored respiration and 
dyspnea. The animal will also prefer to stand with the elbows abducted to relieve thoracic pain 
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and increase chest capacity. CBPP will often develop into a chronic disease demonstrating ill 
thrift and a recurrent low-grade fever that may be difficult to interpret as pneumonia. Forced 
exercise may encourage coughing. In the infected calf, clinical signs may present as arthritis and 
joint swelling instead of pulmonary tropism (OIE 2009).  
 
 Diagnosis 
A clinician should suspect CBPP in a herd with pulmonary signs in adult cattle and 
arthritis in calves co-existing (OIE 2009). According to John Campbell of the Merck Veterinary 
Manual (2019), a diagnosis should be made based on clinical signs and gross characteristic 
lesions of the lungs. The OIE describes these lesions as often unilateral. The affected pulmonary 
parenchyma has no odor. The primary lesion is consolidation of individual lung lobules that 
become encased in widened interlobular septa (strands of connective tissue separating adjacent 
pulmonary acini – where the alveoli are located – and lobules), resulting in a marbled look. 
Interlobular septa become distended by edema, fibrin, and eventually, fibrosis. M. mycoides will 
produce a necrotizing toxin called galactan that will allow for the spread throughout the septa. A 
copious amount of yellow or turbid exudate in the pleural cavity will coagulate to form large 
clots. The pleura of the chest cavity will thicken and become inflamed, producing fibrous 
deposits. In recovered animals, there will be sequestrate with a fibrous capsule surrounding grey 
necrotic tissue (OIE 2009). In terms of diagnostic tests, the Merck Veterinary Manual notes that 
complement fixation (measuring the amount of complement available in serum to bind to an 
antibody-antigen complex), latex agglutination (measuring the number of antibodies or antigens 
in a sample of body fluid), or competitive ELISA tests can be used as an aid. Another 
confirmation can be made by isolating M. mycoides followed by growth inhibition or 
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immunofluorescence test using hyperimmune rabbit sera against M. mycoides. PCR is becoming 
increasingly popular as a diagnostic tool as well. Additionally, serologic reactions can be 
confirmed via immunoblotting test (searches for antibodies against M. mycoides proteins). 
Overall, it is strongly recommended that once an outbreak has occurred, or is suspected to have 
occurred, infected cattle should be slaughtered and submitted for necropsy for diagnosis 
(Campbell 2019).  
 
 Treatment 
In Africa, there is one >60-year-old vaccine formulation (live T1/44) that appears to 
poorly protect animals, cause severe reactions if not administered properly, and has residual 
virulence. Moreover, a mathematical model has shown that even mass vaccination over a five-
year period cannot eradicate CBPP unless other strategies are additionally used (Nicholas et al., 
2012). The effectiveness of antibiotics is difficult to assess, and there is a need to reduce their 
use in a general, profession-wide effort to limit antimicrobial resistance. However, the harsh 
spread of CBPP throughout Africa (in addition to the lack of an effective vaccine) has caught the 
attention of official bodies, including the Food and Agriculture Organization of the United 
Nations (FAO), to reconsider the use of antibiotics (Nicholas et al., 2008).  
Nicholas et al. (2012) recalls use of antimicrobials to treat an outbreak of CBPP in the 
Caprivi region of Namibia in Africa in 2003. This outbreak was severe with high mortality in 
cattle. Locals implemented vaccination policies to protect the naïve animals; however, animals 
continued to die. There was significant concern that this would endemically spread to other areas 
of Namibia with high cattle populations. Nicholas demonstrated in previous experiments that 
CBPP treatment with danofloxacin, a broad-spectrum fluoroquinolone used in treating 
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respiratory disease in a few varying species, could reduce transmission of M. mycoides. With this 
outbreak, Nicholas et al. (2012), therefore, treated all clinically affected or seropositive herds 
with danofloxacin according to the label. The amount of new cases fell instantaneously (only 
three animals died within the first three months after treatment) and no new cases developed 
afterwards. Subsequent monitoring continued for two years, and no new cases were reported. 
Vaccination was implemented once again following the last outbreak. Since this major outbreak 
and the use of antimicrobial treatment, there have been only minor outbreaks east of Caprivi. To 
provide some background information associated with this outbreak, the cattle infected there had 
not been treated earlier due to seasonal flooding of the Zambezi River. Most notably, there have 
been no reported cases in the primary cattle region southwest of Caprivi. This eradication 
treatment success was significant in that CBPP can normally persevere indefinitely in small 
populations. It is demonstrated that an antimicrobial with mycoplasmacidal properties can 
greatly reduce transmission to susceptible animals to a non-sustainable level in a herd (Nicholas 
et al., 2012). Furthermore, some evidence has suggested that antimicrobial treatment hurries the 
healing process by promoting fibrosis in the lung, thus helping to combat M. mycoides 
transmission (Nicholas et al., 2012).  
In vitro antibiotic susceptibility testing of 41 isolates of the mycoplasma pathogen 
revealed that at least 10 antimicrobials demonstrated effectiveness (Nicholas et al., 2012); 
antimicrobial resistance in these treatments has not yet been apparent. Work still needs to be 
done to understand the current field conditions and to find appropriate, cost-effective 
antimicrobials with a proper dosing regimen. Monitoring resistance is also critical (Nicholas et 
al., 2012). Despite the evidence of Nicholas, the OIE (2009) does not recommend antibiotic 
treatment because it can cause a delay in disease recognition, potentially create chronic carriers, 
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and contribute to antimicrobial resistance. All in all, at this stage, there is no standard protocol 
for the treatment of CBPP caused by M. mycoides.  
 
 Prevention & Control 
The OIE (2009) recommends both sanitary and medical prophylaxis. Within the realm of 
sanitary prophylaxis in disease-free areas, quarantine, control of cattle movement, serological 
screening, and culling of all positive and suspect animals is recommended. Contrary to the 
previous section with regard to antibiotics, the OIE recommends vaccination in control of CBPP 
(although they acknowledge the potential of severe adverse reactions). The OIE notes that 
current vaccine strains are made with live, attenuated M. mycoides strains whose efficacy is 
directly related to the virulence of the original strain in production. Additionally, they describe 
two strains used to prepare the CBPP vaccine: the T1/44 strain, which is naturally mild and 
isolated in 1951 in Tanzania (passaged 44 times through embryonated eggs), and the T1sr strain, 
which is evidently completely avirulent but has a shorter immunity than T1/44. In areas where 
CBPP is not prevalent, including Europe (in its proximity to Africa), vaccination is not 
recommended as it can interfere with screening surveillance serological tests (OIE 2009).  





Chapter 4 - Mycoplasma ovipneumoniae (M. ovi) 
 Introduction to Disease 
Mycoplasma ovipneumoniae, referred to in short as M. ovi, is a common respiratory 
pathogen affecting sheep and goats. According to the United States Department of Agriculture 
(USDA) Animal and Plant Health Inspection Service (APHIS) (2015), this bacterium was first 
isolated in 1974 in New Zealand; since then, it has been recovered from the respiratory tracts of 
both healthy and clinically affected sheep worldwide. Alone, M. ovi is not normally highly 
pathogenic, but it predisposes sheep to other respiratory infections, making the resulting 
pneumonia a polymicrobial infection (Besser et al., 2017). This occurs via interference with 
normal ciliary activity in the respiratory tract and by lymphocyte suppression (APHIS 2015).  
In a study completed by the USDA’s National Animal Health Monitoring System in 
2011, 22 major sheep-producing states were evaluated for their health and management. This 
was the first study to estimate the prevalence of M. ovi within the United States. They discovered 
a high percentage of PCR- and ELISA-positive flocks, suggesting that M. ovi is a ubiquitous 
organism among national flocks. All herded-range flocks involved in the study tested positive for 
M. ovi carriage. Moreover, a higher percentage of medium and large flocks tested positive than 
small flocks. DNA fragment detection via nasal swab of ewes demonstrated carriage and 
possible shedding, but not necessarily that of an active infection. The ability of an animal to 
respond to potential exposure relies on many factors including, but not limited to, weather, flock 




In United States sheep operations, respiratory diseases incur significant economic losses. 
According to APHIS, in 2009, 4.8% of nonpredator death losses in sheep and 12.6% of 
nonpredator death losses in lambs were caused by respiratory disease, such as pneumonia or 
shipping fever. Other economic losses based on the respiratory disease manifestation itself in 
sheep included poor growth rates, decreased feed-conversion efficiency, and increased labor and 
management costs (APHIS 2015). A 2011 estimate of economic impact due to M. ovi was 
determined to be $800 million annually in the United States (Highland, n.d.).  
 
 Transmission & Clinical Signs and Symptoms 
In a study performed by Besser et al. (2017), they stated that M. ovi carried by domestic 
goats was transmitted to comingled bighorn sheep, and thus, this prompted the development of 
pneumonia. In this study, though, they found that the severity of disease was significantly milder 
than that seen in similar experiments with domestic sheep strains of M. ovi. Domestic goats (or 
sheep) may transmit other respiratory pathogens when contacting bighorn sheep (or other 
wildlife) on or near wild home ranges, due to stray animals from farms, when used for weed 
control, when commercial operations graze on public lands near wildlife ranges, or when used as 
pack animals for backcountry recreation. Sometimes wildlife will enter private lands as well 
(Besser et al., 2017).  
In a separate study conducted by Besser et al. (2014), they concluded that M. ovi was 
most likely the principal epizootic agent of bighorn sheep pneumonia. The study objective was to 
better evaluate the outcome of experimental introduction of M. ovi into naïve bighorn sheep. 
Some of the most impactful findings in the study were the high transmissibility of M. ovi and the 
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consistent development of pneumonia that followed infection in bighorn sheep. Eight of nine 
bighorn sheep exposed to M. ovi via comingling with a challenged animal developed severe 
bronchopneumonia and three died, while all domestic sheep in the study remained healthy. The 
discussion states that they demonstrated that experimental inoculation of M. ovi infection in 
naïve bighorn sheep produces chronic, severe bronchopneumonia associated with multiple 
secondary bacterial infections. This infection was transmitted quickly to animals both within the 
same pen as well as to animals in adjacent pens. Altogether, respiratory disease, such as 
bronchopneumonia, can be expected with infection of M. ovi. Subsequent signs associated with 
respiratory disease can also be expected (e.g., ill thrift) (Besser et al., 2014). 
 
 Implications to Wildlife 
Despite many early reports of the species tropism for sheep, M. ovi has been implicated 
in species beyond that of the subfamily Caprinae. Since M. ovi’s original isolation, there has 
been evidence supporting its connection with bighorn sheep pneumonia in western North 
America. Other reports of respiratory disease associated with M. ovi have included a few 
muskoxen as well as respiratory disease in Beira antelope in Qatar and at least 9 cattle in 
Colorado, United States (Highland et al., 2018). These studies could be considered by some to be 
somewhat questionable, though, as the methods used to identify M. ovi was limited to PCR 
testing, where no additional diagnostics or sequencing were performed. As stated by Highland et 
al. (2018), definitive claims of host range restrictions are absent from mycoplasma literature, 
because “assumptions about restricted host range of mycoplasmas, based on the host from which 
they were first or frequently isolated, are usually made in the context of nearly complete absence 
of representative sampling of the vast majority of potential vertebrate hosts.” Additionally, the 
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particular and unpredictably culturable nature of M. ovi often requires molecular technologies for 
identification and confirmation. Highland et al. (2018) used such molecular techniques to 
analyze species from the subfamily Capreolinae for M. ovi.  
M. ovi has recently infiltrated into the state of Alaska. The Alaska Department of Fish 
and Game (ADF&G) released a statement on their website of common questions and answers 
regarding M. ovi. To begin with, there is little known about the status of mycoplasmas, including 
M. ovi, in Alaska. The site states that M. ovi was first detected in Alaska’s Dall’s sheep and 
mountain goats in March 2018. In June 2018, M. ovi was found in caribou and moose. 
During July 2017-January 2018, the U.S. Department of Agriculture Research Service in 
Pullman, Washington received nasal swab samples from 230 moose and 243 caribou from 
Alaska as well as 5 mule deer from Arizona. They also received one M. ovi isolate in February 
2018 that had been cultured in Minnesota from the lung tissue of a white-tailed deer that had 
died during a pneumonia outbreak at a captive facility in the upper Midwest U.S. in 2016. They 
ultimately detected M. ovi in 6 moose (2.6%), including 3 from two of the captive facilities and 3 
from free-ranging moose. M. ovi was detected in 5 free-ranging caribou (2.1%) and 2 of 5 mule 
deer, one of which was exhibiting a cough and nasal discharge during sample collection 
(Highland et al., 2018). 
With regard to wildlife health status, finding M. ovi in wildlife does not necessarily mean 
the animal is “diseased,” as there have been M. ovi isolates found in healthy Dall’s sheep, 
mountain goats, caribou, and moose. The ADF&G website also notes that more research and 
monitoring is required to determine if any of the M. ovi strains in Alaska are similar to the 
continental U.S. strains associated with high mortality; thus far, there is no link. It is also 
unknown how M. ovi entered Alaska’s wild sheep and wildlife population. However, the bacteria 
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have been detected in a small number of domestic flocks in Alaska. These flocks were not 
showing signs of illness. The estimated number of domestic sheep and goats in Alaska is 
approximately 1,500. At this point, almost 400 animals have been tested (blood and nasal swabs) 
and about 4% have been found to be positive for M. ovi (ADF&G). Farms participating in 
voluntary testing for the State of Alaska is continuing. Finally, the ADF&G website notes that in 
general, animals showing signs of respiratory disease should be safe to consume. It is 
recommended that affected areas should be trimmed off and the surrounding meat should be 
cooked thoroughly. However, despite not being a foodborne disease, it is recommended that 
wildlife hunters not harvest or consume animals that are visibly ill or are in poor condition as a 
general rule of thumb (ADF&G).  
 
 Diagnosis 
According to Washington State University’s Animal Disease Diagnostic Laboratory 
(WADDL) (2017), there are a few diagnostic methods to detect M. ovi. First, to obtain a sample 
for PCR detection in animals exhibiting pneumonia, the major bronchi can be swabbed and/or a 
sample of consolidated lung tissues can be submitted. If the lung tissue is unavailable, the nose, 
middle ears, or sinuses (especially if purulent exudate is present) can be swabbed instead. In 
healthy appearing or potential carrier animals, both nares of the nose can be deeply swabbed. It is 
advised to use swabs (tip and shaft) made of synthetic materials, and to avoid certain media as 
agar-based transport media can inhibit detection by PCR. If there are testing delays, the samples 
can be frozen for later analysis. Another method for detection of exposure is competitive 
enzyme-linked immunosorbent assay (cELISA). A cELISA test, developed at the WADDL, can 
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be used for M. ovi detection in both bighorn sheep and domestic sheep flocks. The test utilizes 
serum samples where either extracted serum or clotted whole blood may be submitted to the lab.  
The WADDL also advises which diagnostic test(s) to use. Testing by cELISA is sensitive 
and used for determining if a population has had M. ovi exposure. Due to seroprevalence 
variance among bighorn and domestic sheep, the WADDL recommends sampling ten or more 
mountain sheep, 15 or more desert sheep, or 20 or more domestic sheep to reliably ascertain 
exposure status. They do not advise the cELISA for domestic goats, as this assay has not yet 
been validated. Alternately, PCR is utilized to determine the infection status of individual 
animals as well as identifying strain type. They also state that PCR is the most sensitive test for 
determining status in domestic sheep and/or goats because these species typically have a higher 
PCR prevalence than seroprevalence. For biosecurity purposes, if sampling domestic sheep to 
determine individual status, the WADDL recommends a minimum of two negative results from 
samples taken a week or more apart before confirming that the animal is overall negative and not 
infected.    
 
 Treatment 
Scott (2011) claims that treatment is generally not necessary in domestic sheep because 
clinical signs are mild. Scott does, however, suggest that oxytetracycline (single intramuscular 
injection of a long-acting preparation at a dose rate of 20 mg/kg BW) should be administered to 
sick lambs demonstrating inappetence.  
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 Prevention & Control 
Improving building ventilation as well as reducing stocking density within a domestic 
herd can be used to reduce the occurrence of pneumonia. Additionally, newly incoming 
purchased lambs should be isolated and tested before introduction to the homebred stock (Scott 
2011). Separating livestock from wild animals is critical for the protection of both groups.  
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Chapter 5 - Strategies for Controlling Mycoplasma Infection in 
Ruminants 
It is clear that these bacterial species can cause significant damage in many areas, not 
only in terms of animal health and welfare, but also economically. To revisit the three 
mycoplasmas discussed in the previous chapters, please refer to Table 5-1 that provides an 
overview of transmission, clinical signs, diagnosis, and prevention/control. This chapter will also 
review current strategies (including vaccination) and future challenges for controlling this 
infection in ruminants. 
 
Table 5-1: Comparison of the Three Species of Mycoplasma Affecting Ruminants 
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The future of controlling mycoplasma infection in ruminants rests in the theoretical hands 
of vaccination research and development, implementation, and policies. In an era where 
antibiotic resistance is becoming an almost impending doom, reliance on vaccinations to prevent 
disease rather than antibiotics to treat disease is critical. Aggressive attention towards vaccine 
development is a must. Vaccination can be applied to reduce clinical signs as well as lesions, and 
also, to improve performance. Commercial vaccines have also been reported to reduce the 
number of mycoplasma organisms in the respiratory tract and infection level within a herd (Maes 
et al., 2018). Generally, the veterinary focuses for prevention is primarily on herd health rather 
than individual animal health in large animal (livestock) production operations. Unfortunately, 
there is little relevant information regarding vaccination technology for the three discussed 
species of mycoplasma.  
There are, however, relatively recent reviews and studies completed covering these three 
mycoplasma species and vaccine development. The first is a review, published by Perez-Casal et 
al. (2017), noting the status of the development of a vaccine against M. bovis. The review covers 
various challenges toward creating a successful vaccine, to include colonization of young 
animals’ upper respiratory tract, quality and variation of the host immune response, the role of 
other pathogens, such as bovine viral diarrhea virus (BVDV) and bovine herpes virus 1 (BHV-1), 
the need for an appropriate challenge model, and selecting proper adjuvant(s). Moreover, when 
discussing candidates, the review notes that due to a high level of M. bovis antigenic variation, 
key vaccine targets are most likely to be proteins that are conserved across strains, such as 
lipoproteins. When analyzing vaccine efficacy, there has been bacterin formulations; however, 
the studies of these formulations have flaws. For example, the efficacy of a bacterin may be 
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linked to the strain for production and not have broad application. Similarly, vaccine 
development based on recombinant proteins may not produce an ideal protective response. 
Perez-Casal et al. (2017) puts forth that more advanced approaches, such as reverse vaccinology, 
should be utilized to evaluate all potential antigens.  
Next, a study completed by Nkando et al. (2016) covering recombinant M. mycoides 
proteins that elicit a protective immune response against CBPP discusses how new vaccine 
options are necessary. The paper mentions the T1/44 and T1sr vaccines only confer protection 
for less than one year, among other flaws. This study utilized reverse vaccinology from a 
previous study to test 38 bovine-related and 28 caprine-related M. mycoides proteins and their 
ability to promote protection against an experimental CBPP infection. Essentially, the results 
denote that immunization was beneficial and provided protection with some of the antigens, 
while others may have increased immune-related pathology. A future study offered in the 
discussion would be to compare a recombinant vaccine against the current T1/44 live vaccine. 
Lastly, a study completed by Ziegler et al. (2014) tested the safety and immunogenicity 
of a M. ovi bacterin for domestic sheep. The study analyzed three separate immunization 
protocols as follows: 1) live M. ovi (50 g protein); 2) killed M. ovi (50 g whole cell protein) in 
oil adjuvant; and 3) killed M. ovi (250 g whole cell protein) in oil adjuvant. The results found 
that the third protocol provided the most protection to ewes, who were then able to passively 
protect their lambs. Perhaps an intermediate antigenic mass could also produce protective effects.  
Alternately, it seems as there has been more advances made in the vaccine technology for 
other mycoplasma species, particularly Mycoplasma hyopneumoniae; perhaps these efforts can 
be leveraged to approach vaccine development for species like those discussed in the previous 
chapters. In the case of M. hyopneumoniae, it solely affects swine worldwide, and causes a 
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pneumonia that is chronic, relatively clinically mild, and infectiously endemic within a herd. It is 
one of the primary pathogens in the porcine respiratory disease complex. Different vaccination 
strategies are implemented depending on the type of herd, production system, management 
practices, infection pattern, and preferences of the producer (Maes, 2018). However, the exact 
mechanisms of protection are not fully elucidated. Most commercial vaccines are comprised of 
inactivated, adjuvanted whole-cell preparations that are administered intramuscularly. For M. 
hyopneumoniae, bacterin (a suspension of killed or attenuated bacteria) formulations are 
commercially available. However, bacterin efficacy overall towards this species of mycoplasma 
as well as the other discussed species remains to be seen.  
Finances relevant for both the consumer and manufacturer play a major role in 
determining investments in the necessary research to produce an efficacious vaccine. This is 
especially true in the realm of animal health, where financial support for vaccine development is 
only a fraction of what is available for human health. Certain regions of the world where species 
like M. mycoides flourish may experience financial difficulty developing a vaccine compared to 
the United States combating M. bovis, affecting a much larger number of animals across the 
country. One must also consider the complexity of providing vaccines to wildlife, as in the case 
of M. ovi. Prevention in wildlife would realistically fall upon domestic sheep and goat producers 
with herds that may come into contact with wild populations. Wildlife agencies and authorities 
could take on this role, but they are also limited by funding. 
Vaccine technology is currently changing at a relatively rapid pace. We are moving 
beyond first-generation vaccines, such as whole microbial microorganisms that are killed or 
inactivated. Vaccine vector platforms, subunit vaccines, and DNA vaccines are becoming more 
attractive options in animal health that are more rationally designed based on an improved 
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understanding of the pathogenic nature of the organism. However, the cost for these vaccines 
must be relatively inexpensive for a herd production operation. Autogenous vaccines, or bacterial 
isolates from a single farm entity that are inactivated and then combined with an adjuvant, are 
also a possibility. However, it would be better if these diseases could be controlled or prevented 
on a greater scale. New vaccine platforms are among the technologies that could be investigated 
further. Microbial-based vaccine delivery systems are gaining traction, including bacterial 
vectors as vaccine platforms. The selection of a single or combination of adjuvants is also 
fundamental in order to stimulate a significant and appropriate immune response. Other 
technologies, such as DNA printing and Gibson assembly are newer approaches; here, a genome 
can be optimized, compartmentalized, and rapidly constructed for analysis. In the case of 
mycoplasma, for example, the genome/genetic makeup can be rearranged, and thus, the virulence 
of the organism can be attenuated. There is also the technology of the CRISPR Cas9, which 
allows for making changes to either a host or microbial genomes. Repairs/insertions can be made 
to the DNA, which can be done in vivo that appears to be a simple and versatile means of 
genome editing. One problem lies within the conflict of intellectual property ownership at this 
time and stage of development. Moreover, next generation sequencing seems to be the next 
“PCR” of the microbial world. This technology allows for the sequencing of the entire 
genome/microbiome of the organism for gene discovery; seemingly, the primary downside is 
that the amount of bioinformatic data produced can be daunting to complete and interpret in a 
timely manner. Finally, reverse genetics is another technology that can be used. As the name 
implies, one would work backwards from a genome and create/screen for antigenic 
characteristics based on computer-assisted design. Most likely these antigens could be used as 
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vaccine targets; however, it would be equally important to avoid selection of antigens that are too 
immunogenic, creating an intense immune response that adversely affects the animal.  
Overall, mycoplasmas are complex microorganisms to analyze. There is much to be done 






Chapter 6 - Conclusions 
Mycoplasma bacteria have been wreaking havoc over a multitude of species for what 
humans have been aware of for a century. This report focused on three species of mycoplasma 
bacteria affecting ruminants. To summarize, Mycoplasma bovis, a very highly pathogenic 
species, affects cattle and includes clinical signs such as mastitis, pneumonia, ocular signs, 
arthritis, and others. The economic implication of this bacterium makes combating it all the more 
challenging and yet equally important in developing prevention strategies. Laboratory 
diagnostics are necessary to confirm it as the causative agent. Effective treatment of Mycoplasma 
bovis is still unclear at this time, but sound herd management is essential for prevention. In the 
United States, there are some commercial vaccines; however, the options available may not be as 
desirable in efficacy as the animal health industry requires.  
Mycoplasma mycoides, another species affecting cattle and small ruminants, causes 
contagious bovine pleuro-pneumonia. This disease primarily affects herds in Asia and Africa; 
however, there is concern that this disease will spread to current disease-free countries, like the 
U.S. and other countries, and cause major economic impacts. Previously, in the 1800s, American 
and British traders and consumers were severely affected economically by the threat of this 
disease. Mycoplasma mycoides causes respiratory signs in adult cattle and arthritis in calves and 
is transmitted via aerosol. Post-mortem confirmation is required to definitely identify CBPP. 
There is no standard protocol for treatment at this time for M. mycoides, although antimicrobial 
use has been reported. To prevent M. mycoides from entering a herd, sanitary and medical 
prophylaxis are highly recommended, where vaccines are limited.  
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Finally, Mycoplasma ovipneumoniae, affecting domestic sheep and goats as well as 
wildlife, has been increasing in prevalence in the western U.S. as of late. Significant losses are 
seen through respiratory morbidity and the efficiency of transmission. A PCR or cELISA can be 
used to diagnose the disease. To protect both domestic flocks and wildlife herds, domestic 
producers must create a barrier between the groups.  
There are many strategies to combat mycoplasma infections and disease, including herd 
isolation, screening, improving sanitation and ventilation, among other methods. More 
vaccination possibilities and technologies should be explored aggressively, as this strategy could 
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